Antiproliferative Betti Bases and Prodrugs Thereof

Background:

Betti bases are a family of small organic molecules composed of phenolic or hydroxyarl benzylic amine derivatives.  These molecules have established antiproliferative effects on various cancer cell models, believed to originate through interaction with cellular proteins involved in cell signaling for proliferation, such as MDM2, MDMX, p53, E3 ligase, and FTH1.  While traditional cancer therapies have a high incidence of drug resistance, Betti base molecules bypass chemotherapy resistance mechanisms.  Structure-activity relationship analysis identified key components of these drugs required for therapeutic potential.   Molecules 2022, 27(22), 7665; https://doi.org/10.3390/molecules27227665

Technology Overview:

This University at Buffalo invention provided a class of cancer therapeutic molecules derived from Bett base core structures.  Synthesis of a large group of these molecules and subsequent structure-activity relationship analyses identified ideal functional groups to optimize antiproliferative effects in cancer cell models.  Activity assays verified inhibition properties on selected cell proteins involved in anti-proliferation signaling to determine ideal candidates for further work.  Prodrug forms of selected molecules were synthesized, as illustrated in the below figure, to protect targeted functional groups and to provide optimal in vivo performance characteristics and cancer selectivity.

Advantages:

• Prevents cell proliferation
• Immune to chemotherapy resistance mechanisms
• Inexpensive to manufacture

Applications:

• Oncology therapeutics
• Research tool class of molecules for chemical biology studies of cell signaling

Intellectual Property Summary:

PCT/US2023/075454 filed September 28, 2023 WO2024073624A2, WO2024073624A3

Stage of Development:

Laboratory demonstration through in vitro studies and analytical chemical analysis.

Licensing Status:

Available for licensing or collaboration.

Figure 1: